Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Primary Myelofibrosis 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hematopoietic and Lymphatic System Neoplasm 1Graft vs Host Disease 1Cholangiocarcinoma 1Bronchiolitis Obliterans Syndrome 1

Interventions

venetoclax 190Azacitidine 162Cytarabine 127fludarabine 97Cyclophosphamide 75Specimen Handling 68fludarabine phosphate 56Daunorubicin 53Biopsy 49Decitabine 48Whole-Body Irradiation 42Mycophenolic Acid 40Idarubicin 40Busulfan 37Injections 36Tacrolimus 35Granulocyte Colony-Stimulating Factor 35Melphalan 32Stem Cell Transplantation 30gilteritinib 25Filgrastim 25CPX-351 25decitabine and cedazuridine drug combination 23Peripheral Blood Stem Cell Transplantation 22Etoposide 20ivosidenib 19Mitoxantrone 19Cladribine 19Thiotepa 17Sirolimus 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × axatilimab × 1 year × Clear all
NCT07511062 2026-04-06

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

Northside Hospital, Inc.

Phase 1 Not yet recruiting
32 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡